For example, AC-4-130, a STAT5 SH2 domain inhibitor, showed synergistic effects with Ruxolitinib, whereby the low concentration of 1μM for both compounds could reduce the cell viability of MV4-11 and MOLM-13 AML cell lines to below 50% in 24h, which was not observed when the compounds were administered separately [112]. This evidence concerns the gene STAT5B and acute myeloid leukemia.